Apatinib Reactions 1680, p52 - 2 Dec 2017 Various toxicities: case report A man [age at events onsets not clearly stated] developed hand-foot syndrome, elevated BP, headache and loss of appetite during treatment with apatinib [apatinib mesylate; route not stated]. th The man, who was hospitalised on 16 July 2007 for progressive cough, expectoration and suffocation in the chest was later diagnosed with T4N3M0 stage III tracheal adenoid cystic carcinoma. Subsequently, he was started on chemotherapy with cisplatin and paclitaxel along with unspecified acid inhibitors and antiemetics for hepatoprotection. After that, the chemotherapy was discontinued for economical reasons. In November 2007, after receiving two cycles of the chemotherapy, his condition improved slightly and his condition was evaluated as stable disease. Thereafter, in July 2008 and March 2014, he received radiotherapy without any chemotherapy. However, his condition again started to worsen by December 2016. A chest CT showed space occupying lesions in the trachea and the right main bronchus with left pulmonary metastasis. The tumour was classified as T4N×M1, stage IV. In February 2017, he was started on apatinib 500 mg/day. Subsequent improvement was noted in his condition, but he experienced headache, loss of appetite and hand-foot syndrome. Additionally, his BP increased to a maximum of 160/100mm Hg [time to reactions onsets not stated]. The man was treated with valsartan, and his BP normalised [not all outcomes stated]. Author comment: "However, after administration of apatinib mesylate, the patient experienced a headache and his blood pressure increased to a maximum of 160/100 mm/ Hg." "Other adverse reactions included loss of appetite and desquamation of fingers and toes." "The patient experienced minor adverse effects, including hand-foot syndrome, blood pressure elevation, and a slight loss of appetite." Wang H. Case report of apatinib mesylate treatment in rare advanced tracheal adenoid cystic carcinoma. Thoracic Cancer 8: 729-733, No. 6, Nov 2017. Available from: URL: http://doi.org/10.1111/1759-7714.12506 - China 803285337 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial